Around 300 women in England with HER2-negative early breast cancer will be eligible for the new drug each year
The drug could extend patients’ lives by as much as eight months, data suggests
By Cindy Moy Carr and Tami Wahl
Protai aims to increase accuracy in drug discovery and improve the development process
2020 saw an estimated 8.8 million cancer cases in women globally
The boards of directors of both companies have unanimously approved the transaction
Endometrial cancer is the most commonly diagnosed gynaecologic cancer in American women
The designation seeks to streamline the development of new agents with potential to treat serious or life-threatening diseases
